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Background: The transcription factor SOX11 is one of members of the SRY box-containing (SOX) family emerging
as important transcriptional regulators. In recent years, up-regulation of SOX11 has been detected in various types
of solid tumors. In this study, the effects of promoter methylation of the SOX11 gene on SOX11 expression and cell
growth and invasion of nasopharyngeal carcinoma were investigated.
Methods: In this study,methylation-specific PCR and real time quantitative PCR have been applied to investigate the
effect of promoter methylation of the SOX11 gene on SOX11 expression in the nasopharyngeal carcinoma and chronic
inflammation tissues. The nasopharyngeal carcinoma cell line (CNE2) was treated with 5-aza-2'-deoxycytidine. The effect
of promoter methylation of SOX11 on growth and invasion of nasopharyngeal carcinoma cells was detected with MTT
test and Boyden chamber Matrigel invasion assay.
Results: No or weak expression of SOX11 mRNA was detected in the nasopharyngeal carcinoma tissues of SOX11 gene
promoter methylation. Strong expression of SOX11 mRNA was detected in the nasopharyngeal carcinoma tissues of
SOX11 gene promoter unmethylation and chronic inflammation tissues of pharynx nasalis. SOX11 mRNA and protein
were re-expressed, SOX11 gene was demethylated, and growth and invasion of cells were inhibited in CNE2 cell line
after 5-aza-2'-deoxycytidine treatment.
Conclusions: The results of the study indicate that expression of SOX11 mRNA and protein were related to SOX11
gene methylation status. SOX11 gene methylation may be plays a role in growth and invasion of nasopharyngeal
carcinoma cells.
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Nasopharyngeal carcinoma (NPC) is a common tumor in
the head and neck. There are a high incidence of NPC in
south of China. Its pathogenesis is not very clear. It may
be related to a variety of factors. In recent years, epigenesis
of gene attracted much attention from researchers. Abnor-
mality of DNA methylation is an important mechanism of
epigenetic regulation. Methylation status of gene promoter* Correspondence: zhangsongent@foxmail.com
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reproduction in any medium, provided the oris related to gene activity [1,2]. DNA methylation plays an
important role in tumorigenesis. CpG island methylation
of tumor suppressor gene resulted in inactivation of the
gene transcription has become an important part of can-
cer epigenetics research. Multiple tumor suppressor genes
inactivated by promoter CpG island methylation have
been found in a variety of tumor tissues and cells. Such as
promoter hypermethylation and BRCA1 inactivation in
sporadic breast and ovarian tumors [3], hypermethylation
of the APC (adenomatous polyposis coli) gene promoter
region is involved in human colorectal carcinoma [4],
incidence and functional consequences of hMLH1 pro-
moter hypemethylation in colorectal carcinoma[5],Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anism of E-cadherin inactivation in human carcinomas
[6]. The transcription factor SOX11 is one of members
of the SRY box-containing (SOX) family emerging as
important transcriptional regulators, which as a whole
controls cell fate and differentiation [7]. Twenty SOX
genes have been identified in mouse and human ge-
nomes. All SOX genes contain a DNA-binding high mo-
bility group (HMG) domain and protein specific
domains implicated in activation and repression of gene
transcription [8]. It has been found that SOX11 plays an
important role in the development of nervous system
and adult neurogenesis [9,10]. SOX11 up-regulation has
been detected in various types of solid tumors, such as
gliomas and epithelial ovarian tumors [11,12]. Vegliante
found that SOX11 expression is related to methylation
of SOX11 gene promoter in lymphoid neoplasms [13].
In the present study, we have performed on methyla-
tion of SOX11 gene, inclouding DNA methylation in the
tissues of nasopharyngeal carcinoma and DNA demeth-
ylation in the CNE2 cell line (human nasopharyngeal
carcinoma cell line). The findings shows that weak ex-
pression of SOX11 is related to methylation of SOX11
gene promoter in the tissues of nasopharyngeal carcin-
oma, and SOX11 re-expression is associated with de-
methylation of SOX11 gene by 5-aza-2'-deoxycytidine
treated in CNE2 cells.
Material and methods
Clinical material
Fifty-six tissues specimens of pharynx nasalis were in-
cluded in the study. All the biopsies were obtained from
patients with consent before treatment at the Department
of Otolaryngology of Guangming New District People’s
Hospital of Shenzhen. The ratio of male patients and
female patients is 4.6 to 1. The age range was 16–62 years
with a mean age of 49 years. All specimens were subjected
to histological diagnosis by a pathologist. There are forty-
three nasopharyngeal carcinoma (NPC) and thirteen
chronic inflammation tissues. 43 nasopharyngeal carcin-
oma tissues are all undifferentiated nasopharyngeal car-
cinoma. On the basis of TNM stage classification (UICC
2002), 7 (16.3%) patients had stage I disease, 13 (30.2%)
patients had stage II disease, 11 (25.6%) patients had stage
III disease, 12(27.9%) patients had stage IV disease. As for
lymph node metastasis in the neck, 29 patients had lymph
node metastasis, and 14 patients had no lymph node me-
tastasis. No chemotherapy or radiotherapy was given to
patients with nasopharyngeal carcinoma before biopsy.
Analysis of methylation status of SOX11 gene promoter
The methylation status of the SOX11 gene promoter
was determined by chemical modification with the
Methylation-Gold Kit (Zymo Research, Los Angeles, USA)according to the manufacturer’s protocol and the
methylation-specific PCR (MSP) procedure. Primer se-
quences for the methylated (M) sequence: 5'- CGTGT
TCGAGTGTGTGTATTC-3'(sense),5'-GAAACGAACCG
AAATAATTCG -3' (antisense);For the unmethylated (U)
sequence:5'-GTGTGTTTGAGTGTGTGTATTTGG-3' (sense),
5'-CAAAACAAACCAAAATAATTCA-3' (antisense). Amplifi-
cation was carried out in a Life Express Thermal Cycler
for 35 cycles. The annealing temperature for both the
unmethylated and methylated reactions was 56°C. The
PCR products were analyzed on a 2% agarose gel.
RNA isolation and real-time quantitative PCR
The total RNA was isolated from tissues or cells by using
Trizol regents. Reverse transcription was performed with
Revert Aid First Strand cDNA Synthesis Kit. The cDNA
was amplified by following TOYOBO THUNDERBIRD
SYBR qPCR Mix kit with the following primer specific
either for SOX11 or the house-keeping gene β-actin
(primers were synthesized by Invitrogen Biotechnology
Co., LTD). β-actin: 5'-GTCCACCGCAAATGCTTCTA-
3'and5'- TGCTGTCACCTTCACCGTTC-3',SOX11:5'-A
AGAACATCACCAAGCAGCACC-3' and 5'-TGTGA
ACACCAGGTCGGAGAAG-3'. Real-time PCR products
were detected using SLAN Fluorescence Quantitative
PCR Detection System. The β-actin gene was used as in-
ternal control.
Western blot analysis
Total nuclear extracts were isolated and analyzed on a
SDS-polyacrylamide gel and transferred onto a polyvi-
nylidene difluoride membrane. Immunoblotting was
performed using a sheep polyclonal antibody SOX11
and an anti-β-actin antibody. The membranes were
washed with Tris-buffered saline and then incubated
with a 1:3000 dilution of secondary antibodies. The
proteins were visualized by using a chemiluminescence
detection kit from Perkin-Elmer.
Cell culture
The CNE2 cell line, a NPC cell line, was obtained from
the China Center for Type Culture Collection. CNE2
cell line was cultured in RPMI-1640 medium (HyClone,
Sout Logan, UT) supplemented with 10% (v/v) fetal bo-
vine serum (Sijiqing Biological Engineering Materials
Co, Hangzhou, China) at 37°C in 5% CO2.
MTT test
The proliferation assays were performed by MTT test.
The CNE2 cell lines were digested using 0.25% trypsin
when the cells were in the logarithmic phase of growth.
Then, the cell lines were seeded at a concentration of
1 × 105 cells/ml. The cells were seeded onto 96-well
plates at a density of 1 × 104 cells/well in triplicates, and
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Then, the medium containing 5-aza-2'-deoxycytidine (5-
aza-cdr, 0、0.5、1、5、10、20、40、80、160 μmol/L)
was added in each well in 96-well plates. Meanwhile,
zeroing wells were arranged in these plates. 50 μl of MTT
solution (5 mg/mL) was added in each well after the cells
have been cultured for 24 hours. The clear supernatant li-
quid was blotted and 200 μl of dimethyl sulphoxide
(DMSO) was added into each well 2 hours later. The light
absorption of solution at 570 nm was determined by using
a microplate reader. The inhibition ratio of the drug to the
cells was calculated with a formula(IR = (1- experimental
group)/control group × 100%.).
Boyden chamber Matrigel invasion assay
The invasive capacity of control group (without 5-aza-cdr)
and experimental group (with 80 μmol/l 5-aza-cdr) of
CNE2 cells had been examined by using two compart-
ments: Boyden chambers assay (Corning incorporated,
New York, USA) and Matrigel basement membrane
matrix (BD Biosciences, New Jersey, USA). All cells were
analyzed for their viability, and an equal number of viable
cells (105) was added to the upper chamber and allowed to
invade through the Matrigel onto the filters for 24 hours.
At the end of the incubation period, the filters were
washed, fixed, and stained. The invading cells were then
examined and counted in 10 randomly selected fields
under a light microscope at × 400 Magnification. Then,ten
random fields for each set of experiments were analyzed
and the average number of cells invaded was calculated.
Statistical analysis
All statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS,version17.0). Chi-squareFigure 1 Methylation status of SOX11 gene in the nasopharyngeal ca
product with primers recognizing methylated sequences; Lane U, Amplified
SOX11 gene methylated nasopharyngeal carcinoma tissues; Tu: SOX11 gen
inflammation tissues in pharynx nasalis. The results showed that only meth
with SOX11 gene promoter methylation, only unmethylated product was a
carcinoma tissues with SOX11 gene promoter unmethylation.test was used to assess the difference of SOX11 gene
methylation between with lymph node metastasis and with-
out lymph node metastasis in the neck and among each
TNM stage in the nasopharyngeal carcinoma. The t test
was used to assess the difference of invasion capacity of
CNE2 cells before and after 5-aza-cdr treatment. A P value
less than 0.05 was considered statistically significant.Results
Methylation status of SOX11 gene in nasopharyngeal
carcinoma and chronic inflammation tissues
SOX11 gene promoter methylation was found in 29 of 43
(67.4%) nasopharyngeal carcinoma tissues. None of 13
chronic inflammation tissues of pharynx nasalis showed
SOX11 gene promoter methylation (Figure 1). Chi-square
test showed that there was no significant difference in
methylation rate of the SOX11 gene promoter among the
samples from patients with nasopharyngeal carcinoma in
different TNM stages. However, the methylation rate of
the SOX11 gene promoter in the nasopharyngeal carcin-
oma tissues from patients with lymph node metastasis is
significantly higher than nasopharyngeal carcinoma tissues
from patients without lymph node metastasis (Table 1).Expression of SOX11 mRNA in nasopharyngeal carcinoma
and chronic inflammation tissues
No expression or very weak expression of SOX11 mRNA
was detected in the nasopharyngeal carcinoma tissues with
SOX11 gene promoter methylation. Strong expression of
SOX11 mRNA was found in the nasopharyngeal carcin-
oma tissues with SOX11 gene promoter unmethylation
and chronic inflammation tissues of pharynx nasalis
(Figure 2).rcinoma and chronic inflammation tissues. Lane M, Amplified
product with primers recognizing unmethylated sequences. Tm:
e unmethylated nasopharyngeal carcinoma tissues; Ci: Chronic
ylated product was amplified in the nasopharyngeal carcinoma tissues
mplified in the chronic inflammation tissues and nasopharyngeal
Table 1 Clinical characteristics in the total cohort and the
SOX11 gene methylation positive subgroup
History N
total
N SOX11 gene methylation
positive








Lymph node metastasis **
Positive 29 25
Negative 14 4
* X2 = 1.930, P = 0.587.
** X2 = 5.233, P = 0.000.
Figure 2 SOX11 mRNA expression in the nasopharyngeal
carcinoma and chronic inflammation tissues. A, Electrophoretogram
of SOX11 mRNA expression; B, Electrophoretogram of β-actin mRNA
expression; Tm: SOX11 gene methylated nasopharyngeal carcinoma
tissues; Tu: SOX11 gene unmethylated nasopharyngeal carcinoma
tissues; Ci: Chronic inflammation tissues in pharynx nasalis. It showed
that weak expression of SOX11 mRNA was found in the nasopharyngeal
carcinoma tissues with SOX11 gene promoter methylation, strong
expression of SOX11 mRNA was found in the chronic inflammation
tissues and nasopharyngeal carcinoma tissues with SOX11 gene
promoter unmethylation.
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carcinoma and chronic inflammation tissues
Weak expression of SOX11 protein was detected in the
nasopharyngeal carcinoma tissues with SOX11 gene pro-
moter methylation. Strong expression of SOX11 protein
was showed in the nasopharyngeal carcinoma tissues
with SOX11 gene promoter unmethylation and chronic
inflammation tissues of pharynx nasalis (Figure 3).
MTT test
The MTT test showed that the inhibition of cells
growth is more and more obvious with the increase of
drug concentration. When the drug concentration is
80 μmol/L, the inhibition rate of cells growth is almost
50% (Figure 4).
Effect of 5-aza-cdr on invasion capacity of CNE2 cells
The invasive capacity of control group (without 5-aza-cdr)
and experimental group (treatment with 5-aza-cdr) CNE2
cells had been examined by using Boyden chamber Matri-
gel invasion assay. As expected, the invading cells number
was significantly decreased in the CNE2 cells treated withFigure 3 SOX11 protein expression in the nasopharyngeal carcinoma
nasopharyngeal carcinoma tissues; Tu: SOX11 gene unmethylated nasopha
nasalis. The electrophoretogram showed that weak expression of SOX11 pr
gene promoter methylation, strong expression of SOX11 protein was found
tissues with SOX11 gene promoter unmethylation.5-aza-cdr(=8.40 ± 1.26) than the CNE2 cells without any
treatment(=12.10 ± 1.20, t = 6.718, p = 0.000). These stud-
ies show that invasive capacity of CNE2 cells treated with
5-aza-cdr was significantly decreased than CNE2 cells
without any treatment (Figure 5).and chronic inflammation tissues. Tm: SOX11 gene methylated
ryngeal carcinoma tissues; Ci: Chronic inflammation tissues in pharynx
otein was found in the nasopharyngeal carcinoma tissues with SOX11
in the chronic inflammation tissues and nasopharyngeal carcinoma
Figure 4 Growth inhibition plot of CNE2 cells after treated by 5-aza-cdr. The plot showed that CNE2 cell growth inhibition is more and
more obvious with the increase of 5-aza-cdr concentration. When the 5-aza-cdr concentration is 80 μmol/L, the inhibition rate of CNE2 cells
growth ratio is almost 50%.
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CNE2 cells
In order to detect the effect of 5-aza-cdr on methylation of
SOX11 gene in the CNE2 cells, 105 CNE2 cells were
seeded onto 6-well plates in each well and incubated for
24 hours. Then, the medium containing 5-aza-cdr (80 μM)
was added randomly to 3 wells. The other 3 wells were not
added anything. All CNE2 cells in 6-well plates were
digested using 0.25% trypsin after incubating 48 hours. The
methylation status of SOX11 gene was detected by using
methylation-specific PCR in the CNE2 cells. The results
showed that SOX11 gene was demethylated after treating
with 5-aza-cdr in the CNE2 cells (Figure 6).
Effect of 5-aza-cdr on expression of SOX11 mRNA and
protein in the CNE2 cells
In order to detect the effect of 5-aza-cdr on expression
of SOX11 mRNA and protein in the CNE2 cells, 105
CNE2 cells were seeded onto 6-well plates in each well,
and treated the cells using the same methods above.Figure 5 Effect of 5-aza-cdr on CNE2 cells invasion capacity. A, CNE2 c
80 μmol/L 5-aza-cdr. Invasive capacity of CNE2 cells treated with 5-aza-cdrCNE2 cells in 6-well plates were digested with 0.25%
trypsin after incubating 48 hours. RT-PCR and Western
Blot results showed that re-expression of SOX11 mRNA
and protein was found after treating with 5-aza-cdr in
CNE2 cells (Figures 7 and 8).
Discussion
The transcription factor SOX11 plays an important role in
embryonic development of the central nervous system
and in developing neuron growth and survival as well as
recovery of adult neurons following injury tissue [9,10,14].
Several studies have recently demonstrated that SOX11 is
up-regulated in various solid tumors, such as lymphoid
neoplasms [15], gliomas and epithelial ovarian tumors
[11,12]. Brennan [12] revealed that a strong nuclear ex-
pression of SOX11 in epithelial ovarian cancer, which cor-
related with a prolonged recurrence-free survival. So, he
suggested that SOX11 plays a functional role in regulation
of tumor growth. Hide detected that over-expression of
SOX11 prevents tumorigenesis of human glioma initiatingells were not treated by any drugs; B, CNE2 cells were treated by
was significantly decreased than CNE2 cells without any treatment.
Figure 6 Effect of 5-aza-cdr on SOX11 gene methylation in the
CNE2 cells. Lane M, Amplified product with primers recognizing
methylated sequences; Lane U, Amplified product with primers
recognizing unmethylated sequences. Only methylated product was
amplified in the CNE2 cells without any treatment. Only
unmethylated product was amplified in the CNE2 cells after treated
by 5-aza-cdr. It showed that SOX11 gene was demethylated by
5-aza-cdr in the CNE2 cells.
Figure 7 Effect of 5-aza-cdr on SOX11 mRNA expression in the CNE2
Electrophoretogram of β-actin mRNA expression. From the electrophoretog
80 μmol/L 5-aza-cdr treated.
Figure 8 Effect of 5-aza-cdr on SOX11 protein expression in the
CNE2 cells. The result showed that re-expression of SOX11 protein
was found in the CNE2 cells after 80 μmol/L 5-aza-cdr treated.
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be epigenetically silenced through DNA methylation in a
subset of B cell malignancies [17]. In this study, the
expression and methylation status of SOX11 gene was de-
tected in nasopharyngeal carcinoma and chronic inflam-
mation tissues of pharynx nasalis. We found that weak
expression of SOX11 correlate with methylation of SOX11
gene in nasopharyngeal carcinoma tissues.
Epigenetic mechanism of gene included DNA methyla-
tion, histone modifications and RNA interference. DNA
methylation is the main epigenetic event in humans, and
changes in the DNA methylation pattern play an import-
ant role in tumorigenesis [18]. In recent years, the study
of tumor suppressor gene promoter methylation has be-
come an important content in occurrence and develop-
ment of cancer. Many studies have demonstrated thatcells. A, Electrophoretogram of SOX11 mRNA expression; B,
ram, re-expression of SOX11 mRNA was found in the CNE2 cells after
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methylated in a variety of human cancers [19-21]. DNA
methylation is a reversible biochemical modification [22].
The transcriptional inactivation of tumor suppressor gene
caused by CpG island methylation can be reversed with
DNA methyltransferase inhibitor (5 - aza-2'-deoxycyti-
dine). The reversal (CpG island demethylation) can re-
store the expression of tumor suppressor gene, and then
inhibit cell proliferation and tumor growth [23]. There-
fore, restoring the expression of tumor suppressor genes
by using DNA methyltransferase inhibitors has become
one of the new means of cancer gene therapy. The previ-
ous study demonstrated that loss of DAPK expression is
associated with aberrant promoter region methylation in
nasopharngeal cancer cell line(CNE2) and laryngeal cancer
cell line(Hep-2), 5 - aza-2'-deoxycytidine may reactivate
DAPK genes silenced by promoter region hypermethyla-
tion and can slow the growth of Hep-2 cells and CNE2
cells in vitro and in vivo [24,25]. In the study, the changes
of growth and invasion of cells have been detected after
being treated with 5 - aza-2'-deoxycytidine in CNE2 cells.
The data showed that the inhibition of CNE2 cell growth
increased with the increase of drug concentration, invasive
capacity of CNE2 cells was significantly decreased, re-
expression of mRNA and protein of SOX11 was detected,
and SOX11 gene was demethylated after treating with 5-
aza-cdr in the CNE2 cells. These results showed that re-
expression of SOX11 mRNA and protein may be one of
the factors which decrease the growth and invasion cap-
acity of CNE2 cells. Because 5 - aza-2'-deoxycytidine is a
DNA methyltransferase inhibitor. It can be reversed the
methylated gene in the course of DNA copy.
Nasopharyngeal carcinoma is a common tumor in head
and neck. The rradiotherapy is main treatment of naso-
pharyngeal carcinoma. In recent years, although the tech-
nique and equipment of radiotherapy progressive
updating, but the therapeutic effect of nasopharyngeal car-
cinoma is not greatly improved. It is because pathogenesis
of nasopharyngeal carcinoma is not very clear. Many stud-
ies have explored the pathogenesis and therapeutic effect
of nasopharyngeal carcinoma. Most of these studies are
genetics and epigenetics. The study of tumor suppressor
gene promoter methylation is paid increasing attention. In
previous study, we treated CNE2 cells using 5 - aza-2'-
deoxycytidine, its proliferation and growth were signifi-
cantly inhibited, and re-expression of DAPK gene si-
lenced through DNA methylation was found in CNE2
cells [24]. In the present study, after CNE2 cells were
treated with 5 - aza-2'-deoxycytidine, SOX11 gene was
demethylated and re-expressed, the growth and inva-
sion of CNE2 cells were inhibited. The growth and inva-
sion inhibition of CNE2 cells is probably associated with
re-expression of various tumor suppressor genes. The
SOX11 gene is one of those tumor suppressor genes.Therefore, SOX11 gene methylation may play a role in
growth and invasion of nasopharyngeal carcinoma cells.
Conclusions
In conclusion, the data provides a comprehensive char-
acterization of the epigenetic mechanisms about SOX11
deregulation in nasopharyngeal carcinoma. No or weak
expression of SOX11 gene was detected in some nasopha-
ryngeal carcinoma tissues with DNA methylation. Strong
expression of SOX11 gene was found in chronic inflam-
mation tissues of pharynx nasalis and some nasopharyn-
geal carcinoma tissues with DNA unmethylation. After
CNE2 cells were treated with 5 - aza-2'-deoxycytidine,
SOX11 gene expression was recovered,and growth and in-
vasion of CNE2 cells were inhibited. It showed that
SOX11 expression may be one of the factors that decrease
the growth and invasion capacity of CNE2 cells. In a word,
additional studies are required to elucidate which is the
functional role of the illegitimate SOX11 expression in
nasopharyngeal carcinoma.
Abbreviation
SOX: SRY box-containing; NPC: Nasopharyngeal carcinoma;
MSP: Methylation-specific PCR; 5-aza-cdr: 5-aza-2'-deoxycytidine.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
The work presented here was carried out in collaboration between all
authors. SZ and SL defined the research theme, designed methods and
experiments; J-LG carried out the laboratory experiments, analyzed the data,
interpreted the results and wrote the paper. All authors read and approved
the final manuscript.
Acknowledgement
This project was supported by Guangdong Province medical research Project
(series number: A2012606).
Author details
1Department of Otolaryngology, Guang Ming New District People’s Hospital
of Shenzhen, Song Bai Road 339#, Shenzhen, Guang Dong TX 518106, PR
China. 2Department of Otolaryngology, Nanshan People’s Hospital of
Shenzhen, Tao Yuan Road 89#, Shenzhen, Guang Dong TX 518052, PR China.
Received: 30 May 2013 Accepted: 1 November 2013
Published: 5 November 2013
References
1. Razin A, Riggs AD: DNA methylation and gene function. Science 1980,
210:604–610.
2. Bird AP: CpG-rich islands and the function of DNA Bird methylation.
Nature 1986, 321:209–213.
3. Esteller M, Silva JM, Dominguez G: Promoter hypermethylation and BRCA1
inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst
2000, 92:564–569.
4. Hiltunen MO, Alhonen L, Koistinaho J: Hypermethylation of the APC
(adenomatous polyposis coli) gene promoter region in human colorectal
carcinoma. Int J Cancer 1997, 70:644–648.
5. Herman JG, Umar A, Polyak K: Incidence and functional consequences of
hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl
Acad Sci USA 1998, 95:6870–6875.
6. Yoshiura K, Kanai Y, Ochiai A: Silencing of the E-cadherin invasion-suppressor
gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA
1995, 92:7416–7419.
Zhang et al. Cancer Cell International 2013, 13:109 Page 8 of 8
http://www.cancerci.com/content/13/1/1097. Lefebvre V, Dumitriu B, Penzo-Mendez A, Han Y, Pallavi B: Control of cell
fate and differentiation by Sry-related high-mobility-group box (Sox)
transcription factors. Int J Biochem Cell Biol 2007, 39:2195–2214.
8. Schepers GE, Teasdale RD, Koopman P: Twenty pairs of sox: extent,
homology, and nomenclature of the mouse and human sox
transcription factor gene families. Dev Cell 2002, 3:167–170.
9. Haslinger A, Schwarz TJ, Covic M, Chichung Lie D: Expression of Sox11 in
adult neurogenic niches suggests a stage-specific role in adult
neurogenesis. Eur J Neurosci 2009, 29:2103–2114.
10. Jankowski MP, Cornuet PK, McIlwrath S, Koerber HR, Albers KM: SRY-box
containing gene 11 (SOX11) transcription factor is required for neuron
survival and neurite growth. Neuroscience 2006, 143:501–514.
11. Weigle B, Ebner R, Temme A, Schwind S, Schmitz M: Highly specific
overexpression of the transcription factor SOX11 in human malignant
gliomas. Oncol Rep 2005, 13:139–144.
12. Brennan DJ, Ek S, Doyle E, Drew T, Foley M: The transcription factor Sox11
is a prognostic factor for improved recurrence-free survival in epithelial
ovarian cancer. Eur J Cancer 2009, 45:1510–1517.
13. Vegliante MC, Royo C, Palomero J, Salaverria I, Balint B: Epigenetic
activation of SOX11 in lymphoid neoplasms by histone modifications.
PLoS ONE 2011, 6(6):e21382.
14. Jay P, Goze C, Marsollier C, Taviaux S, Hardelin JP: The human SOX11 gene:
cloning, chromosomal assignment and tissue expression. Genomics 1995,
29:541–545.
15. Dictor M, Ek S, Sundberg M, Warenholt J, Gyorgy C: Strong lymphoid
nuclear expression of SOX11 transcription factor defines lymphoblastic
neoplasms, mantle cell lymphoma and Burkitt’s lymphoma.
Haematologica 2009, 94:1563–1568.
16. Hide T, Takezaki T, Nakatani Y, Nakamura H, Kuratsu J, Kondo T: SOX11
prevents tumorigenesis of glioma-initiating cells by inducing neuronal
differentiation. Cancer Res 2009, 69:7953–7959.
17. Gustavsson E, Sernbo S, Andersson E, Brennan DJ, Dictor M, Jerkeman M,
Borrebaeck CA, Sara EK: SOX11 expression correlates to promoter
methylation and regulates tumor growth in hematopoietic malignancies.
Mol Cancer 2010, 9:187.
18. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer.
Nat Rev Genet 2002, 3:415–428.
19. Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T,
Hermeking H: Detection of miR-34a promoter methylation in
combination with elevated expression of c-Met and β-catenin predicts
distant metastasis of colon cancer. Clin Cancer Res 2013, 19(3):710–720. 1.
20. Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N: Methylation of tumor
suppressor genes in ovarian cancer. Exp Ther Med 2012, 4(6):1092–1096.
21. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD,
Gazdar AF, Schorge JO: Promoter hypermethylation profile of ovarian
epithelial neoplasms. Clin Cancer Res 2005, 11:5365–5369.
22. Ramchandani S, Bhattacharya SK, Cervoni N, Szyf M: DNA methylation is a
reversible biological signal. Proc Natl Acad Sci USA 1999, 96:6107–6112.
23. Lyko F, Brown R: DNA methyltransferase inhibitors and the development
of epigenetic cancer therapies. J Natl Cancer Inst 2005, 97:1498–1506.
24. Kong WJ, Zhang S, Guo CK, Wang YJ, Chen X, Zhang SL: Effect of
methylation-associated silencing of the deathassociated protein kinase
gene on nasopharyngeal carcinoma. Anticancer Drugs 2006, 17:251–259.
25. Kong WJ, Zhang S, Guo C, Zhang S, Wang Y, Zhang D: Methylation-associated
silencing of death-associated protein kinase gene in laryngeal squamous
cell cancer. Laryngoscope 2005, 115:1395–1401.
doi:10.1186/1475-2867-13-109
Cite this article as: Zhang et al.: Promoter methylation status of the
tumor suppressor gene SOX11 is associated with cell growth and
invasion in nasopharyngeal carcinoma. Cancer Cell International
2013 13:109.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
